Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksJudges Scientific Regulatory News (JDG)

Share Price Information for Judges Scientific (JDG)

Share Price is delayed by 15 minutes
Get Live Data
4,625.00    -50.00 (-1.07%)
Bid:
4,500.00
Ask:
4,750.00
Spread: 250.00 (5.556%)
Market Cap: £308.06m
JDG Live PriceLast checked at - London Stock Exchange

Intraday Judges Scientific Share Chart

Acquisition and Trading Update

27 Jun 2013 07:00

RNS Number : 9611H
Judges Scientific PLC
27 June 2013
 



Judges Scientific plc

 

ACQUISITION OF SCIENTIFICA LIMITED

 

27 June 2013

 

JUDGES SCIENTIFIC plc

("Judges Scientific", "Judges", the "Company" or the "Group")

ACQUISITION OF SCIENTIFICA LIMITED AND TRADING UPDATE

Judges Scientific, the parent company of a group engaged in the design, manufacture and sale of scientific instruments, announces that on 26 June 2013 it acquired 100% of the issued share capital of Scientifica Limited ("Scientifica"), specialist manufacturers of electrophysiology equipment, for a cash consideration of £12.0 million and an earn-out capped at £1.0 million (the "Acquisition").

An additional payment will be made to reflect any excess working capital over and above the ongoing requirements of the business. Judges expects such payment to be covered by the cash inherited as at the completion date.

Information on Scientifica

Scientifica designs, manufactures and sells complete instrument rigs used in electrophysiology, comprised of micromanipulators, optical microscopes and associated mounting solutions. The company also distributes a range of complementary products including imaging systems, multi-electrode arrays, amplifiers, perfusion equipment and light sources. The products are sold worldwide to academic institutions, research centres and pharmaceutical companies for the purpose of conducting electrophysiology research with a particular emphasis on neuroscience.

Scientifica was founded in 1996 by Mark Johnson and David Rogerson, who developed it as joint Managing Directors and who each owned a 50% interest in the company's share capital. During recent months, Matt Kemp joined the senior management team as Sales Director. Shortly before completion, Mr Kemp exercised options to acquire 5% of the enlarged equity, thereby reducing the respective holdings of Mr Johnson and Mr Rogerson to 47.5% each. Following the Acquisition, Mr Rogerson will not stay with the company, which will be run by Mr Johnson and Mr Kemp who will remain in their respective positions.

The company has concentrated its operations on the supply of systems, which are configured to meet the specific requirements of individual customers. This customer focus has enabled Scientifica to achieve a compound annual growth rate of 31% over the past five years. Exports represent two-thirds of total revenues and Scientifica's performance in overseas markets was recognised in 2012 when the company received a Queen's Award for Enterprise - International Trade.

Scientifica's unaudited accounts for the financial year to 31 March 2013 show revenues of £9.2 million and pre-tax profits of £2.2 million. Operating profit adjusted to eliminate non-recurring items and to reflect Judges' practices would have totalled £2.1 million. The accounts show net tangible assets of £3.65 million, including cash of £1.25 million.

The earn-out will amount to £1.0 million if Scientifica generates operating profits of £2.167 million or more in respect of the twelve month period to 31 March 2014, reducing by six times any shortfall below £2.167 million. Half of the earn-out will be paid in cash and half through the issue of new Ordinary shares ("Ordinary Shares") in Judges at a price of 1180p per Ordinary Share, based on the prevailing price of Judges' Ordinary Shares on the day the Acquisition was agreed in principle. For accounting purposes, fluctuations in the share price will have a commensurate impact on the book value of the earn-out cap.

The Acquisition is expected to be earnings enhancing with immediate effect. The Board believes that Scientifica is an excellent business operating in an expanding niche with considerable worldwide growth potential.

Financing of the Acquisition

As at 31 December 2012, the date of the last published balance sheet, the Group's adjusted net debt amounted to £1.7 million supported by borrowing facilities of £10.7 million. The Acquisition and associated transaction costs are being financed from existing cash resources and an additional £9.0 million term loan ("Loan") provided by Lloyds Bank Corporate Markets. The Loan is repayable over a five year period.

Judges' Trading Performance

The Group's trading performance since the beginning of the current financial year has remained satisfactory. Order intake was strong in the first quarter and more subdued since, resulting in 4.7% organic growth in order intake compared to the first 25 weeks of 2012. This is consistent with market expectations for the year as a whole.

Alex Hambro, Chairman of Judges, commented:

"The purchase of Scientifica represents the largest acquisition made by Judges Scientific and its impact on the Group's financial performance should be significant. We are delighted that Mark Johnson and Matt Kemp will continue to manage the company and we welcome them to Judges' expanding team."

 

For further information please contact:

Judges Scientific Plc

David Cicurel, CEO

Tel: 01342 323 600

 

Shore Capital (Nominated Adviser & Broker)

Edward Mansfield

Tel: 020 7408 4090

 

Cardew Group (Financial Public Relations)

Melvyn Marckus

Tel: 020 7930 0777 or 07775 896 491

 

Websites:

Judges Scientific: www.judges.uk.com 

Scientifica: http: www.scientifica.uk.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACQFFMMTMBBTTJJ
Date   Source Headline
29th Sep 20142:49 pmRNSHolding(s) in Company
24th Sep 20147:00 amRNSHalf Yearly Report
16th Sep 20147:00 amRNSNotice of Results
10th Sep 20147:00 amRNSDirector/PDMR Shareholding
8th Aug 20142:29 pmRNSDirector/PDMR Shareholding
22nd Jul 20147:00 amRNSDirector/PDMR Shareholding
18th Jul 20143:14 pmRNSHolding(s) in Company
17th Jul 20147:00 amRNSTrading Statement
9th Jul 20145:24 pmRNSDirector/PDMR Shareholding
6th Jun 20143:52 pmRNSDirector/PDMR Shareholding
5th Jun 201412:03 pmRNSIssue of Equity
3rd Jun 20144:15 pmRNSDirector/PDMR Shareholding
23rd May 20143:20 pmRNSExercise of options
22nd May 20147:00 amRNSPayment of deferred consideration for Scientifica
19th May 20143:08 pmRNSExercise of options
12th May 20141:54 pmRNSDirector/PDMR Shareholding
24th Apr 20145:30 pmRNSExercise of Options
10th Apr 201412:01 pmRNSExercise of options
8th Apr 20146:15 pmRNSDirector/PDMR Shareholding
4th Apr 20142:28 pmRNSExercise of Options
28th Mar 20147:00 amRNSFinal Results
10th Mar 201410:00 amRNSNotice of Results
10th Mar 20148:51 amRNSDirector/PDMR Shareholding
7th Feb 20142:53 pmRNSDirector/PDMR Shareholding
24th Jan 20147:00 amRNSTrading Statement
22nd Jan 20142:01 pmRNSExercise of Options
13th Jan 20141:40 pmRNSHolding(s) in Company
10th Jan 20146:00 pmRNSHolding(s) in Company
9th Jan 20144:34 pmRNSDirector/PDMR Shareholding
13th Dec 201310:31 amRNSIssue of Equity
10th Dec 20138:39 amRNSDirector/PDMR Shareholding
4th Dec 20134:06 pmRNSIssue of Equity
26th Nov 20133:31 pmRNSDirector/PDMR Shareholding
20th Nov 20137:00 amRNSTrading Statement
7th Nov 20132:04 pmRNSDirector/PDMR Shareholding
25th Oct 20135:24 pmRNSHolding(s) in Company
25th Oct 20134:19 pmRNSDirector/PDMR Shareholding
21st Oct 20137:00 amRNSPlacing to raise GBP8.125 million
9th Oct 20131:25 pmRNSDirector/PDMR Shareholding
2nd Oct 20135:47 pmRNSHolding(s) in Company
26th Sep 20137:00 amRNSHalf Yearly Report
17th Sep 20134:17 pmRNSNotice of Results
9th Sep 20134:15 pmRNSDirector/PDMR Shareholding
13th Aug 201312:48 pmRNSHolding(s) in Company
6th Aug 20134:33 pmRNSDirector/PDMR Shareholding
18th Jul 20132:04 pmRNSDirector/PDMR Shareholding
18th Jul 20137:00 amRNSTrading Statement
15th Jul 20134:59 pmRNSExercise of Options
10th Jul 20131:27 pmRNSExercise of options
9th Jul 20137:00 amRNSDirector/PDMR Shareholding and Issue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.